Critical Care · 2015 · 108 citations · 40 references
MedicineHematologyInflammationTransfusion MedicineTrauma Critical CareAcute InflammationBlood Transfusion ManagementBlood Transfusion SafetyMassive Transfusion ProtocolsEndothelial Cell DamageEndothelial InflammationFresh Frozen Plasma TherapyInflammatory Cytokine EffectsPlasma Transfusion SafetySystemic Inflammation MarkersTransfusion In Trauma CareTrauma Massive Transfusion
INTRODUCTION: Much controversy exists on the effect of a fresh frozen plasma (FFP) transfusion on systemic inflammation and endothelial damage. Adverse effects of FFP have been well described, including acute lung injury. However, it is also suggested that a higher amount of FFP decreases mortality in trauma patients requiring a massive transfusion. Furthermore, FFP has an endothelial stabilizing effect in experimental models. We investigated the effect of fresh frozen plasma transfusion on systemic inflammation and endothelial condition. METHODS: A prospective predefined substudy of a randomized trial in coagulopathic non-bleeding critically ill patients receiving a prophylactic transfusion of FFP (12 ml/kg) prior to an invasive procedure. Levels of inflammatory cytokines and markers of endothelial condition were measured in paired samples of 33 patients before and after transfusion. The statistical tests used were paired t test or the Wilcoxon signed-rank test. RESULTS: At baseline, systemic cytokine levels were mildly elevated in critically ill patients. FFP transfusion resulted in a decrease of levels of TNF-α (from 11.3 to 2.3 pg/ml, P = 0.01). Other cytokines were not affected. FFP also resulted in a decrease in systemic syndecan-1 levels (from 675 to 565 pg/ml, P = 0.01) and a decrease in factor VIII levels (from 246 to 246%, P <0.01), suggestive of an improved endothelial condition. This was associated with an increase in ADAMTS13 levels (from 24 to 32%, P <0.01) and a concomitant decrease in von Willebrand factor (vWF) levels (from 474 to 423%, P <0.01). CONCLUSIONS: A fixed dose of FFP transfusion in critically ill patients decreases syndecan-1 and factor VIII levels, suggesting a stabilized endothelial condition, possibly by increasing ADAMTS13, which is capable of cleaving vWF. TRIAL REGISTRATIONS: Trialregister.nl NTR2262, registered 26 March 2010 and Clinicaltrials.gov NCT01143909, registered 14 June 2010.
40
Hematological Problems in Pediatric Intensive Care
Shoshana Revel‐Vilk, Peter N. Cox, Nancy Robitaille et al. · Pediatric and adolescent medicine · 2013 · 3.5K citations
Matthew A. Borgman, Philip C. Spinella, Jeremy G. Perkins et al. · The Journal of Trauma: Injury, Infection, and Critical Care · 2007 · 1.6K citations
Medicine, Hematology, Hemostasis +16